1. Search Result
Search Result
Results for "

anticancer effects

" in MedChemExpress (MCE) Product Catalog:

494

Inhibitors & Agonists

3

Screening Libraries

2

Fluorescent Dye

3

Biochemical Assay Reagents

12

Peptides

7

Inhibitory Antibodies

201

Natural
Products

22

Isotope-Labeled Compounds

2

Click Chemistry

13

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13670

    GI147211; OSI-211

    Topoisomerase Cancer
    Lurtotecan (GI147211; OSI-211), a semisynthetic Camptothecin analog, is a topoisomerase I inhibitor. Lurtotecan has anticancer effects .
    Lurtotecan
  • HY-N3369

    Longistyline C

    Others Cancer
    Longistylin C (Longistyline C) is a natural stilbene with anticancer effects .
    Longistylin C
  • HY-N10797

    Others Cancer
    (-)-Haplomyrfolin is a natural lignan with anticancer effects .
    (-)-Haplomyrfolin
  • HY-160219S

    Btk Cancer
    BTK-IN-33 is a Btk inhibitor with anticancer effects (WO2023174300A1; compound I) .
    BTK-IN-33
  • HY-N6579

    Others Cancer
    Arvenin I is a natural cucurbitacin glucoside with moderate anticancer effects .
    Arvenin I
  • HY-115709

    Drug Intermediate Cancer
    4,6-O-Benzylidene-D-glucose is a benzaldehyde derivative with anticancer effects .
    4,6-O-Benzylidene-D-glucose
  • HY-13670A

    GI147211 dihydrochloride; OSI-211 dihydrochloride

    Topoisomerase Cancer
    Lurtotecan dihydrochloride (GI147211), a semisynthetic Camptothecin analog, is a topoisomerase I inhibitor. Lurtotecan dihydrochloride has anticancer effects .
    Lurtotecan dihydrochloride
  • HY-162114

    PARP Cancer
    PARP1-IN-18 (compound 25) is a potent PARP1 inhibitor with an IC50 value of 2.7 nM. PARP1-IN-18 has anticancer effects .
    PARP1-IN-18
  • HY-150255

    IGF-1R Insulin Receptor Cancer
    IMP2-IN-3 is a potent IMP2 inhibitor. IMP2-IN-3 shows anticancer effects .
    IMP2-IN-3
  • HY-N3722

    Others Cancer
    O-Demethylmurrayanine is a natural phenol with anticancer effects. O-Demethylmurrayanine exhibits strong cytotoxicity against MCF-7 and SMMC-7721 with IC50 values in the range 4.42-7.59 μg/mL .
    O-Demethylmurrayanine
  • HY-123308

    Androgen Receptor Cancer
    VPC13163 is a potent androgen receptor (AR) BF3 inhibitor with an IC50 of 0.31 µM. VPC13163 has anticancer effects .
    VPC13163
  • HY-N11697

    P-glycoprotein Cancer
    α-Cryptoxanthin is a natural carotenoid with anticancer effects. α-Cryptoxanthin inhibits multidrug resistance 1 (MDR1) mediated efflux pump .
    α-Cryptoxanthin
  • HY-121362

    Bacterial Endogenous Metabolite Inflammation/Immunology Cancer
    Evernic Acid is a secondary metabolite generated by lichens, including Ramalina, Evernia, and Hypogymnia, and several studies have described its anticancer, antifungal, and antimicrobial effects. Neuroprotective and anti-inflammatory effects .
    Evernic Acid
  • HY-N3627

    NSC 680073

    Others Cancer
    Coronalolide methyl ester (NSC 680073) is a natural triterpene with anticancer effects. Coronalolide methyl ester shows moderately cytotoxic to KATO-3, SW-620, and Hep-G2 cells., with IC50 values of 8.64 µg/mL, 6.19 µg/mL, and 6.8 µg/mL, respectively .
    Coronalolide methyl este
  • HY-148974

    Polo-like Kinase (PLK) Cancer
    PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. PLK1-IN-5 shows anticancer effects (WO2008113711A1; compound I-4) .
    PLK1-IN-5
  • HY-158175

    EGFR Cancer
    EGFR T790M/L858R-IN-4 (Example 14) is a potent EGFR T790M/L858R inhibitor with anticancer effects .
    EGFR T790M/L858R-IN-4
  • HY-162245

    PROTACs Epigenetic Reader Domain Cancer
    PROTAC SMARCA2 degrader-3 is a PROTAC degrader of the SWI/SNF ATPase subunits, SMARCA2. PROTAC SMARCA2 degrader-3 has anticancer effects (WO2023244764A1; Compound 153) .
    PROTAC SMARCA2 degrader-3
  • HY-145664

    Wee1 Cancer
    Myt1-IN-1 is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of <10 nM. Myt1-IN-1 has anticancer effects (WO2021195782A1; compound 132) .
    Myt1-IN-1
  • HY-145665

    Wee1 Cancer
    Myt1-IN-2 is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of <10 nM. Myt1-IN-2 has anticancer effects (WO2021195782A1; compound 28) .
    Myt1-IN-2
  • HY-N7535

    Others Cancer
    Chlorovaltrate K is a chlorinated valepotriate with anticancer effects. Chlorovaltrate K shows moderate cytotoxicity against A549, PC-3M, HCT-8 and Bel 7402 cell lines with IC50 values of 2.32-8.26 μM .
    Chlorovaltrate K
  • HY-122782

    Lucialdehyde C

    Glycosidase Metabolic Disease Cancer
    Lucidal (Lucialdehyde C) is a natural lanostante-type triterpene aldehyde that shows inhibitory effects against α-glucosidase (Glucosidase) with an IC50 of 0.635 mM. Lucidal has anticancer and antidiabetic effects .
    Lucidal
  • HY-N3626

    Others Cancer
    Coronalolide is a natural triterpene with anticancer effects. Coronalolide exhibits a broad cytotoxic activity for human breast (BT474), gastric (KATO-3), lung (CHAGO), colon (SW-620), and liver (Hep-G2) cancer cell lines, with IC50 values of 6.59 µg/mL, 5.85 µg/mL, 5.42 µg/mL, 4.98 µg/mL, and 6.41 µg/mL, respectively .
    Coronalolide
  • HY-157330

    P-glycoprotein Apoptosis Cancer
    P-gp inhibitor 16 (compound 14) is a p-glycoprotein inhibitor. P-gp inhibitor 16 significantly increases Doxorubicin-induced apoptosis and shows anticancer effects .
    P-gp inhibitor 16
  • HY-P99538

    LFB-R603; TG-1101; TGTX-1101

    CD20 Cancer
    Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
    Ublituximab
  • HY-157149

    MAP4K Cancer
    DS21150768 is a potent, orally active HPK1 inhibitor. DS21150768 shows potent activity to enhance T-cell function. DS21150768 has anticancer effects .
    DS21150768
  • HY-170814

    G-quadruplex Cancer
    G-quadruplex ligand 3 (Compound 16) is a G-quadruplex ligand with anticancer effects that chelate iron. G-quadruplex ligand 3 stabilizes G-quadruplexes in human leukemia Jurkat cells. G-quadruplex ligand 3 localizes in the cell nucleus, serving as a fluorescent nuclear tracer for the labile iron pool .
    G-quadruplex ligand 3
  • HY-160447

    Aurora Kinase FAK Cancer
    FAK/Aurora kinase-IN-1 is a FAK and aurora kinase inhibitor with IC50 values of 6.61 nM and 0.91 nM, respectively. FAK/Aurora kinase-IN-1 shows anticancer effects (WO2018019252A1; compound 11) .
    FAK/Aurora kinase-IN-1
  • HY-162307

    PROTACs Keap1-Nrf2 Cancer
    Nrf2 degrader 1 (compound 1) is a PROTAC Nrf2 degrader with anticancer effects. Nrf2 degrader 1 inhibits cancer cells growth for A549 and LK-2 cells with IC50 values of 100 nM and 40 nM, respectively .
    Nrf2 degrader 1
  • HY-142922

    Bcr-Abl Cancer
    BCR-ABL-IN-4 is a BCR-ABL inhibitor with anticancer effects. BCR-ABL-IN-4 inhibits the cancer cell growth with IC50 values of 0.67 nM and 16 nM for K562 cells and BCR-ABL T315I transfected Ba/F3 cells, respectively (WO2021143927A1; compound 11) .
    BCR-ABL-IN-4
  • HY-N10354

    Apoptosis Cancer
    27-Methyl withaferin A (comppund 26) is an apoptosis inducer with anticancer effects. 27-Methyl withaferin A shows antiproliferative effects against HeLa, A-549 and MCF-7 human tumor cell lines with IC50 values of 3.2 μM, 4.2 μM and 1.4 μM, respectively .
    27-Methyl withaferin A
  • HY-153276

    Androgen Receptor Cancer
    Androgen receptor-IN-5 is an androgen receptor inhibitor with potent anticancer effects. Androgen receptor-IN-5 also inhibits the production of IL-17A, IL- 17F and INF-γ (WO2023281097A1,Example 1/1) .
    Androgen receptor-IN-5
  • HY-145817A
    lunresertib
    1 Publications Verification

    RP-6306

    Wee1 Cancer
    lunresertib (RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. lunresertib shows a high degree of selectivity over other kinases in cellular binding assays. lunresertib shows anticancer effects .
    lunresertib
  • HY-P99473

    BI-505

    Integrin Cancer
    Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
    Bersanlimab
  • HY-113722

    Microtubule/Tubulin Cancer
    DAT1 is a potent antimitotic agent with anticancer effects. In HeLa cells, DAT1 blocks the spindle function by disturbing spindle microtubule and chromosome organization .
    DAT1
  • HY-153413

    Ras Cancer
    Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566) .
    Kras4B G12D-IN-1
  • HY-158407

    Apoptosis Cancer
    Anticancer agent 220 is a chromanone derivative with anticancer effects. Anticancer agent 220 shows highly potent activity in the colon cancer cell lines. Anticancer agent 220 induces apoptosis and cell cycle arrest in cells .
    Anticancer agent 220
  • HY-N7229

    DNA/RNA Synthesis Cancer
    Rabdosin B is an ent-kaurene diterpenoid with anticancer effects. Rabdosin B induces DNA damage in cells, and inhibits lettuce root hair development of seedlings .
    Rabdosin B
  • HY-124808

    Ras Apoptosis Cancer
    IMM-01 is a mammalian Diaphanous (mDia)-related formins agonist that inhibits DID-DAD (diaphanous inhibitory domain-diaphanous autoregulatory domain) binding with an IC50 of 140 nM. IMM-01 acts by disrupting the autoinhibitory bond between the DID and DAD domain and thus activates formins. IMM-01 shows anticancer effects .
    IMM-01
  • HY-141604

    CDX-011; CR011-vcMMAE

    Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Glembatumumab vedotin (CDX-011) is an ADC (antibody-drug conjugates (ADCs)) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
    Glembatumumab vedotin
  • HY-P99330

    Anti-Human VEGFA Recombinant Antibody; RO5520985

    VEGFR Tie Cancer
    Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
    Vanucizumab
  • HY-168678

    PROTACs Ras Cancer
    pan-KRAS degrader 5 (compound 102) is a potent cereblon-based KRAS PROTAC degrader, with a DC50 of <100 nM. pan-KRAS degrader 5 shows anticancer effects. (Pink: ligand for target protein (HY-168679); Black: linker (HY-168670); Blue: E3 ligase ligand (HY-W580113)) .
    PROTAC K-Ras Degrader-6
  • HY-168669

    PROTACs Ras Cancer
    pan-KRAS degrader 4 (compound 69) is a potent cereblon-based KRAS PROTAC degrader, with a DC50 of <100 nM. pan-KRAS degrader 4 shows anticancer effects. (Pink: ligand for target protein (HY-168671); Black: linker (HY-168670); Blue: E3 ligase ligand (HY-W733895)) .
    PROTAC K-Ras Degrader-5
  • HY-145303

    Oxidative Phosphorylation Mitochondrial Metabolism Cancer
    DX2-201 is a potent and selective oxidative phosphorylation (OXPHOS) complex I inhibitor with an IC50 of 312 nM. DX2-201 has anticancer effects .
    DX2-201
  • HY-149602

    Glutaminase Reactive Oxygen Species Cancer
    Glutaminase C-IN-2 (compound 11) is glutaminase C (GAC) allosteric inhibitor with an IC50 of 10.64 nM. Glutaminase C-IN-2 regulates the cellular metabolite, thereby increasing reactive oxygen species (ROS) by blocking glutamine metabolism. Glutaminase C-IN-2 has anticancer effects .
    Glutaminase C-IN-2
  • HY-151915

    ATM/ATR mTOR Cancer
    ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC50 of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC50 of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .
    ATR-IN-20
  • HY-W846144

    MNK Cancer
    ETP-45835 is slective and potent MNK inhibitor with IC50s of 575 nM and 646 nM for MNK1 and MNK2, respectively. ETP-45835 shows little activity against 24 other kinases. ETP-45835 inhibits eIF4E Ser209 phosphorylation in cells, and has anticancer effects .
    ETP-45835
  • HY-149099

    RET Cancer
    RET-IN-22 (compound 17b) is a potent, selective and orally active RET inhibitor with an IC50 of 20.9 nM and 18.3 nM for wild-type RET and RET-V804M, respectively. RET-IN-22 shows highly selective profile to most kinases, especially to EGFR and VEGFR2. RET-IN-22 has anticancer effects .
    RET-IN-22
  • HY-170365

    MAP4K Inflammation/Immunology Cancer
    HPK1-IN-55 (compound 19) is a selective and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 of <0.51 nM. HPK1-IN-55 shows excellent kinase selectivity (>637-fold vs GCK-like kinase and >1022-fold vs LCK). HPK1-IN-55 has anticancer effects .
    HPK1-IN-55
  • HY-127029A

    NO Synthase Lipoxygenase Neurological Disease Inflammation/Immunology Cancer
    Umbelliprenin, a prenylated coumarin, is an antioxidant with anticancer, anti-inflammatory and immunomodulatory effects. Umbelliprenin inhibits lipoxygenase managing the inflammation pathways. In inflammatory macrophages, Umbelliprenin suppresses nitric oxide production as well as inducible nitric oxide synthase (NO synthase) .
    Umbelliprenin
  • HY-15698A
    CRT0066101 dihydrochloride
    2 Publications Verification

    PKD Pim Apoptosis Inflammation/Immunology Cancer
    CRT0066101 dihydrochloride is a potent and orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively . CRT0066101 dihydrochloride is also a potent PIM2 inhibitor with an IC50 of ~135.7 nM. CRT0066101 dihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects .
    CRT0066101 dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: